Missing/wrong data?
Log in to edit
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial
scientific article published in September 2002
Author/s
author: Josep Baselga, Roy S. Herbst, Waun Ki Hong
Work details
Publication date
September 1, 2002
-
-
Language
English
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.